| Literature DB >> 17112427 |
Frank Rauch1, Francis H Glorieux.
Abstract
Children with moderate to severe forms of osteogenesis imperfecta (OI) require adequate physiotherapy, rehabilitation and orthopedic surgery. Supportive treatment with bisphosphonates can improve the effects of these nonmedicinal treatment modalities. Benefits of bisphosphonate treatment include decreased pain, lower fracture incidence, and better mobility. Among the various bisphosphonates, intravenous pamidronate has been studied in most detail. However, the optimal treatment regimen and the long-term consequences of pamidronate treatment in children are currently unknown. Given these uncertainties, treatment with bisphosphonates during growth should be reserved for patients who have significant clinical problems, such as vertebral compression fractures or long-bone deformities. Medical therapies other than bisphosphonates play a minor role at present. Gene-based therapy currently remains in the realm of preclinical research.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17112427 DOI: 10.1007/s11914-996-0025-2
Source DB: PubMed Journal: Curr Osteoporos Rep ISSN: 1544-1873 Impact factor: 5.096